Revenue ($USD) : $15,113,000,000
R&D spend : $605,000,000.00
Employees : 60,000
Fiscal year end : 12/31/22
CEO : José Almeida

Count Baxter among the major medical device companies seeking to refocus through divestitures.

In January, Baxter announced plans to spin its renal care and acute therapies units into an independent, publicly traded company. Baxter expects the new, independent, publicly-traded company — called Vantive — to launch by July 2024.

Meanwhile, there is uncertain timing around the sale of Baxter’s biopharma solutions (BPS) business. Baxter recently said it plans for the BPS sale to complete toward the end of the third quarter.

Said Baxter CEO José (Joe) Almeida: “These initiatives are focused on enhancing strategic clarity, increasing market responsiveness and accelerating innovation, in an effort to drive greater value for our stakeholders.” –CN